Unlocking the Power of CAR T Cells: A New Approach to Destroying Solid Tumors
Imagine a world where our bodies could be harnessed to fight and destroy solid tumors, like those found in the bowel, pancreas, prostate, and lungs. A team of researchers led by Dr. Sebastian Kobold, a renowned physician at LMU University Hospital, has made a groundbreaking discovery that brings us closer to this reality. In 2024, their research revealed a fascinating mechanism that hinders the body's immune system from targeting cancer cells.
The study, published in the journal Nature Biomedical Engineering, focuses on the metabolite prostaglandin E2 (PGE2) and its ability to block T cells, the immune system's killer cells, near tumor sites. This discovery is crucial because it explains why CAR T cell therapies, which have shown promise in treating certain leukemias and lymphomas, have struggled to make a significant impact against solid tumors. CAR T cells, short for chimeric antigen receptor-modified T cells, are genetically engineered to recognize and attack cancer cells, but PGE2 creates a barrier that prevents them from doing so effectively.
Dr. Kobold's team, in collaboration with Professor Jan Böttcher from the University of Tübingen, has now found a way to overcome this challenge. They modified CAR T cells to prevent PGE2 from binding to them, essentially removing the obstacle that hinders their ability to destroy solid tumors. This innovative approach, detailed in the study, has shown remarkable results in preclinical models and human tumor samples.
The process involves taking T cells from patients, genetically modifying them to produce a specific protein (CD19) on their surface, and then reintroducing them into the body. This modification ensures that CAR T cells can precisely target and eliminate cancer cells. However, solid tumors have evolved mechanisms to render CAR T cells ineffective, making it a complex battle.
Dr. Kobold's team has made significant progress by genetically engineering CAR T cells to prevent PGE2 from binding to them. This modification allows CAR T cells to function optimally, even in the presence of PGE2. The study demonstrated this approach's success in models of breast and pancreatic cancer, as well as in human tumor samples from patients with pancreatic, bowel, and neuroendocrine cancers.
The next step is exciting: clinical trials. While the initial focus will be on lymphomas, which have shown some success with CAR T therapy, the ultimate goal is to test this approach on patients with solid tumors. Dr. Janina Dörr, the lead author, is optimistic about the potential, stating that the findings suggest a higher success rate for therapy with silenced PGE2. If funding is secured, a study on solid tumor patients could follow, bringing us closer to a breakthrough in cancer treatment.
This research highlights the power of scientific collaboration and the importance of understanding the intricate molecular mechanisms behind cancer. As we continue to unravel these complexities, we move closer to a future where CAR T cell therapies can effectively combat a wide range of cancers, offering hope and improved outcomes for patients worldwide.
